Coty Posts Mixed Q4 Results, Joins Wolfspeed, ATRenew And Other Big Stocks Moving Lower In Thursday’s Pre-Market Session

Agenus Says Published Phase 1b Data Showed 21.2-Month Median Overall Survival, 33% Three-Year Overall Survival And 21% Objective Response Rate With Botensilimab Plus Balstilimab In 123 Pretreated MSS Colorectal Cancer Patients

Agenus’ NEST Phase 2 Results Published In Clinical Cancer Research, No Colorectal Cancer Recurrences Observed At Updated Median Follow-Up Of 32.2 Months In NEST-1 And 23.5 Months In NEST-2 In pMMR/MSS Tumors, Neoadjuvant BOT+BAL Achieved 59% Pathologic Response, Including 41% Major Pathologic Response And 32% Pathologic Complete Response

No colorectal cancer recurrences observed at updated median follow-up of 32.2 months in NEST-1 and 23.5 months in NEST-2In pMMR/MSS tumors, neoadjuvant BOT+BAL achieved 59% pathologic response, including 41% major

8-K filing — AGENUS INC (AGEN)

Filed: 2026-08-18 AccNo: 0001193125-26-355559 Size: 146 KB Item 1.01: Entry into a Material Definitive Agreement Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant Item 3.02: Unregistered Sales of Equity Securities

Morgan Stanley Maintains Equal-Weight on Coty, Raises Price Target to $2.75

Morgan Stanley analyst Dara Mohsenian maintains Coty (NYSE:COTY) with a Equal-Weight and raises the price target from $2.5 to $2.75.

8-K filing — COTY INC. (COTY)

Filed: 2026-08-20 AccNo: 0001024305-26-000050 Size: 257 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 9.01: Financial Statements and Exhibits

Coty shares are trading lower after the company reported mixed Q4 financial results and issued Q1 adjusted EPS guidance below estimates. The company disclosed that the Gucci Beauty license exit will result in a step-down in FY28 sales and profit.